PMID- 35788728 OWN - NLM STAT- MEDLINE DCOM- 20230414 LR - 20230414 IS - 1432-1335 (Electronic) IS - 0171-5216 (Linking) VI - 149 IP - 5 DP - 2023 May TI - Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. PG - 1873-1882 LID - 10.1007/s00432-022-04107-w [doi] AB - PURPOSE: To investigate the effectiveness and safety of the combination of sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). METHODS: This study was approved by the ethics committees of six tertiary medical centers in China. Between October 2017 and October 2020, 213 patients with advanced HCC received either sorafenib combined with on-demand DEB-TACE (DTS group, n = 103) or sorafenib monotherapy (S group, n = 110). Overall survival (OS), time to progression (TTP), local tumor response, and adverse events (AEs) were compared between the two groups. RESULTS: The incidences of nause/vomiting, abdonimal pain, hyperbilirubinemia, fever and ALT/AST increasing were higher in the DTS group. The post-treatment partial response, objective response, and disease control rates were significantly higher in the DTS group than in the S group (51.5% vs. 23.6%; 56.3% vs. 25.5%; 77.7% vs. 56.4%, respectively). The median OS was significantly longer in the DTS group than in the S group [16.3 vs. 10.0 months; hazard ratio (HR) = 0.43; P < 0.001], as was the TTP (6.7 vs. 4.3 months; HR = 0.60; P = 0.001). In the DTS group, patients who received >/= 2 sessions of DEB-TACE benefited more than those who received two sessions of DEB-TACE. Multivariate analysis revealed that the alpha-fetoprotein level and treatment allocation were independent predictors of OS and TTP. CONCLUSION: The combination of sorafenib and DEB-TACE is safe and effective for the treatment of early ISPA-HCC. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Fan, Wenzhe AU - Fan W AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Zhu, Bowen AU - Zhu B AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Zheng, Xinlin AU - Zheng X AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Yue, Shufan AU - Yue S AD - Department of Medical Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Lu, Mingjian AU - Lu M AD - Department of Radiology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, People's Republic of China. FAU - Fan, Huishuang AU - Fan H AD - Interventional Department, Dongguan People's Hospital, Dongguan, People's Republic of China. FAU - Qiao, Liangliang AU - Qiao L AD - Department of Oncology, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Li, Fuliang AU - Li F AD - Liver and Gall Surgical Department, Gaozhou People's Hospital, Gaozhou, People's Republic of China. FAU - Yuan, Guosheng AU - Yuan G AD - Department of Gastroenterology, Nanfang Hospital, Guangzhou, People's Republic of China. FAU - Wu, Yanqin AU - Wu Y AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Zou, Xinhua AU - Zou X AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Wang, Hongyu AU - Wang H AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Xue, Miao AU - Xue M AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. FAU - Li, Jiaping AU - Li J AUID- ORCID: 0000-0003-2927-8877 AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. lijiap@mail.sysu.edu.cn. LA - eng GR - 81971719/National Natural Science Foundation of China/ GR - 2021A1515010548/Natural Science Foundation of Guangdong Province/ GR - A2020081/Guangdong Provincial Applied Science and Technology Research and Development Program/ PT - Journal Article DEP - 20220705 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 9ZOQ3TZI87 (Sorafenib) SB - IM MH - Humans MH - *Carcinoma, Hepatocellular/drug therapy MH - Sorafenib MH - *Liver Neoplasms/drug therapy MH - *Chemoembolization, Therapeutic/adverse effects MH - Treatment Outcome MH - Retrospective Studies OTO - NOTNLM OT - Hepatocellular carcinoma OT - Sorafenib OT - Stage progression OT - Transarterial chemoembolization EDAT- 2022/07/06 06:00 MHDA- 2023/04/14 06:42 CRDT- 2022/07/05 18:45 PHST- 2022/02/04 00:00 [received] PHST- 2022/05/20 00:00 [accepted] PHST- 2023/04/14 06:42 [medline] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/07/05 18:45 [entrez] AID - 10.1007/s00432-022-04107-w [pii] AID - 10.1007/s00432-022-04107-w [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 May;149(5):1873-1882. doi: 10.1007/s00432-022-04107-w. Epub 2022 Jul 5.